current
spread
around
world
pose
signific
threat
global
health
economi
convalesc
plasma
confirm
effect
novel
corona
viru
preliminari
studi
paper
first
describ
therapeut
schedul
antibodi
detect
method
indic
contraind
convalesc
plasma
report
oper
treatment
case
studi
decemb
pneumonia
associ
novel
corona
viru
caus
outbreak
pose
signific
threat
global
health
economi
china
share
chines
experi
world
standard
treatment
summar
therapeut
schedul
convalesc
plasma
follow
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
inclus
criteria
six
criteria
must
met
week
onset
symptom
complet
resolut
symptom
least
day
prior
donat
accord
reliev
isol
discharg
standard
follow
latest
version
therapeut
schedul
age
year
old
weight
histori
bloodtransmit
diseas
elig
donor
must
assess
clinician
accord
treatment
histori
pregnanc
transfus
whose
hna
antibodi
hla
antibodi
posit
individu
physic
condit
elig
assess
clinician
interv
plasma
collect
two
week
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
novel
coronaviru
nucleic
acid
test
neg
defin
titer
novel
coronavirusspecif
igg
antibodi
serumplasma
antibodi
titer
higher
hepat
b
surfac
antigen
hepat
c
antibodi
hiv
antibodi
treponema
pallidum
antigen
test
neg
alanin
aminotransferas
well
within
normal
rang
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
longterm
week
posit
novel
coronaviru
nucleic
acid
test
detail
pleas
refer
patient
congenit
iga
defici
accord
principl
crossmatch
blood
abo
homogen
plasma
prefer
slow
infus
requir
first
minut
order
pay
attent
occurr
advers
reaction
blood
transfus
show
outcom
three
individu
patient
convalesc
plasma
transfus
characterist
donorreceiv
shown
supplementari
tabl
particip
gave
written
inform
consent
approv
hospit
ethic
committe
first
patient
treat
convalesc
plasma
th
day
admiss
viral
nucleic
acid
test
becam
neg
critic
ill
turn
sever
second
therapi
conduct
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
improv
significantli
discharg
criteria
met
day
learn
case
convalesc
plasma
treatment
quickli
turn
viral
nucleic
acid
test
neg
significantli
reduc
symptom
second
case
patient
whose
nucleic
acid
test
consist
posit
moder
symptom
treatment
th
day
viral
nucleic
acid
test
turn
neg
four
day
later
therefor
order
save
medic
resourc
reduc
transmiss
infect
advis
use
convalesc
plasma
treatment
patient
longterm
week
posit
nucleic
acid
test
novel
coronaviru
third
case
plasma
donor
woman
histori
pregnanc
supplementari
tabl
addit
viral
load
convalesc
plasma
treatment
significantli
lower
day
intens
care
unit
admiss
found
patient
longterm
posit
nucleic
acid
test
novel
coronaviru
turn
neg
earlier
convalesc
plasma
treatment
without
convalesc
plasma
treatment
furthermor
asymptomat
patient
hypoimmun
elderli
children
patient
underli
diseas
diabet
hepat
aid
heart
diseas
tuberculosi
malign
tumor
etc
prefer
use
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
